Ivosidenib Promising Against Refractory Bile Duct Cancer Ivosidenib Promising Against Refractory Bile Duct Cancer
Ivosidenib improved progression-free survival in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma in a phase 3 placebo-controlled trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Bile | Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Health | Hematology